Global Pharmaceuticals: exploring a rapidly evolving marketplace
As the US policy overhang has subsided, pharmaceutical companies face a shifting set of risks and opportunities. In this webinar, we'll provide an updated global pharmaceutical sector outlook, with a focus on how innovation trends and emerging sales channels are shaping credit profiles. We'll also discuss the evolving M&A landscape as companies further aim to mitigate patent expirations and regulatory pricing pressures, while re-positioning portfolios for the next phase of growth.
Discussion topics include:
- Key earnings growth drivers in 2026-2027 across branded pharma, with a focus on the GLP-1 market opportunity juxtaposed against escalating pricing pressures.
- A detailed look at industrywide patent risks that will peak in 2028-2029, while conversely highlighting the growth opportunity for biosimilars and generics.
- Our M&A outlook for 2026, including the possibility of larger & transformative deals.
- A closer look at the implications from MFN pricing deals, including the rising advent of the direct-to-consumer channel.
Speakers
Ola Hannoun-Costa
Associate Managing Director, Corporate Finance
Moody’s Ratings
Michael Weinstein
Vice President- Senior Credit Officer
Moody’s Ratings
Michael Levesque
Senior Vice President
Moody's Ratings
Marie Fischer-Sabatié
Senior Vice President, Corporate Finance
Moody's Ratings
Francesco Bozzano
Vice President – Senior Analyst, Corporate Finance
Moody's Ratings
Vladimir Ronin
Vice President - Senior Analyst
Moody’s Ratings
Confirm cancellation
An error occurred trying to play the stream. Please reload the page and try again.
Close